
|Articles|April 26, 2004
Proprietary sustained-release dexamethasone implant shows promise for treating persistent cystoid macular edema
Results of a controlled Phase I/II study show that the bioerodable, sustained-release,dexamethasone implant (Posurdex, Allergan) results in a statistically significantincrease in ETDRS standardized visual acuity in eyes with persistent cystoidmacular edema (CME), said Mark S. Blumenkranz, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Evolving glaucoma therapy: A new era of interventional strategies
2
Precision strategy: Optimizing visual outcomes with advanced small-aperture lenses
3
Throwback Series: Managing bilateral diabetic macular edema early in practice
4
ICYMI: AAO 2025 showcases new technologies and continued research
5

















































.png)


